Answers are grounded in this paper and cite their sources.
Aim To design and fabricate composite magnetic nanoparticles (MNPs), Fe3O4@Au(Cy5.5)-DOPE/PNPO-siRNA, for the diagnosis and treatment of ovarian cancer (adenocarcinoma cells).Materials and methods Fe3O4@Au(Cy5.5)-DOPE/PNPO-siRNA nanoparticles were synthesized using seed growth and chemical reduction methods. The fabricated Fe3O4@Au nanoparticles were systematically characterized and evaluated. For in vitro studies, the anti-tumor effects were assessed in naturally resistant SKOV3 ovarian adenocarcinoma cells. Cellular uptake, gene-silencing efficiency, and cytotoxicity assays were conducted to determine their therapeutic potential. For in vivo studies, a xenograft mouse model harboring SKOV3 tumors was established to evaluate magnetic resonance imaging (MRI) contrast enhancement and biosafety of nanoparticles. MRI was performed using T2-weighted imaging (T2WI) to monitor tumor accumulation and signal changes. The biosafety was further examined through histopathological analysis of major organs.Results We successfully designed and fabricated Fe3O4@Au composite magnetic nanoparticles (MNPs) encapsulated with surface lipids, which exhibited excellent biocompatibility and safety. These Fe3O4@Au composite MNPs effectively delivered PNPO-siRNA into SKOV3 cells, enabling both ovarian cancer treatment and MRI. In vivo MRI of SKOV3 tumor-bearing mice showed effective tumor accumulation of nanoparticles. T2WI revealed a peak signal reduction of approximately 17% at 3h post-injection (ANOVA, compared to the pre-injection group, ***p < 0.001), followed by gradual recovery over time. These findings indicate that Fe3O4@Au MNP can serve as effective negative MRI contrast agent to enhance ovarian cancer detection. For therapeutic evaluation, Fe3O4@Au(Cy5.5)-DOPE/PNPO-siRNA nanoparticles significantly inhibited SKOV3 cell proliferation in vitro. Furthermore, biosafety assessments demonstrated no significant toxicity in major organs, supporting their potential for as a safe and effective platform for the treatment of ovarian cancer.Conclusion Fe3O4@Au(Cy5.5)-DOPE/PNPO-siRNA composite magnetic MNPs demonstrate significant potential as dual-function agents, serving both as MRI tracers and as molecular therapeutic platforms for ovarian cancer in vivo.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: